

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Kenneth Brasel et al.

Docket No.: 2836-D

RECEIVED
CENTRAL FILE CENTER

JAN 12 2005

Serial No: 09/448,378

Group Art Unit: 1644

Filed: November 23, 1999

CPA Filed: June 28, 2001

RCE Filed: January 12, 2005


Examiner: P. Gambel, PhD.

For: METHODS OF USING FLT3-LIGAND FOR
AUGMENTING AN IMMUNE RESPONSE
FOR THE TREATMENT OF CANCER
(AS AMENDED)

MAIL STOP RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF COMMON OWNERSHIP

U.S. Patent Application Serial No. 09/448,378 and PCT International Patent Application No. WO 94/28391 were owned by, or subject to an obligation of assignment to, Immunex Corporation at the time the invention of U.S. Patent Application Serial No. 09/448,378 was made. Immunex Corporation is a wholly owned subsidiary of Amgen Inc.


James E. Klaniacki
Applicants' Representative
Reg. No. 38,207

Date: JAN 12, 2005

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, Washington 98119-3105
(206) 265-7000

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below.

Signed: 
Nanci M. Kertson

Date: JAN 12, 2005